Condition 1: Pure hypercholesterolaemia. Condition 2: Mixed hyperlipidaemia. Condition 3: Other hyperlipidaemia. Condition 4: Lipoprotein deficiency. Condition 5: Hyperlipidaemia, unspecified. Familial hypercholesterolaemiaFredrickson hyperlipoproteinaemia, type IIaHyperbetalipoproteinaemiaHyperlipidaemia, group ALow-density-lipoprotein-type [LDL] hyperlipoproteinaemia Broad- or floating-betalipoproteinaemiaFredrickson hyperlipoproteinaemia, type IIb or IIIHyperbetalipoproteinaemia with prebet
Conditions
Interventions
Intervention 1: The intervention group, daily received 300 mg of vitamin E (alfa-Tocopheryle Acetate) (ZAKARIYAYE RAZI manufacturer company), Which is exactly equal to 300 IU, and 400 mg of vitamin C
Placebo
The intervention group, daily received 300 mg of vitamin E (alfa-Tocopheryle Acetate) (ZAKARIYAYE RAZI manufacturer company), Which is exactly equal to 300 IU, and 400 mg of vitamin C (ascorbic acid))
control group, received 2 placebo (A product in terms of physical and chemical properties is quiet similar to C and E vitamins) for one year.
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
28 Years to 13 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Age between 60 to 75 years; literacy rate higher than fifth grade; Exclusion criteria:The lack of a liver disorder, renal failure and mal absorption, any kind of cancer, or any illness that may interfere with the absorption of antioxidants; Smoking, tobacco and drug abuse; taking Vitamin C and E supplementation before entering the study; taking medications that could seriously disrupt lipid metabolism, such as fibrates, nicotinic acid, glucocorticoids; those who at baseline diagnosed hyperlipidemic of course with The experiment was done, and did not receive a medication to control it and required medication; severe disability
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total cholestrol. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;LDL. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;HDL. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry.;TG. Timepoint: at baseline, after 6 mounth, after 1 year. Method of measurement: enzimatically- colorimetry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAmir Mansour Alavi
Tehran University of Medical Sciences
Outcome results
None listed